TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07807241: A Study of MX006 in Patients With Advanced and/or Metastatic Tumors Known to Express B7-H3

Sponsor: Myricx Pharma Limited · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 120 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$9,456,216

Rescue Site Savings

+$6,251,784

Unlock Full NCT07807241 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07807241 Rescue Dossier →